LLY is trading at 3.1% up now at $1103.38 after Bernstein raised its price target to $1,300 from $1,100 on November 25, 2025, citing stronger catalysts ahead for Eli Lilly’s GLP-1 portfolio and the upcoming launch of its oral GLP-1 drug, orforglipron. The stock’s rally is further supported by blockbuster sales of Mounjaro and Zepbound, positive Phase III trial results, and raised full-year guidance following robust Q3 earnings. Investors remain confident in Eli Lilly’s leadership in the obesity and diabetes markets, with analysts projecting continued high growth and market expansion.